EXOZYMES INC. 10-K — AI Bull & Bear Analysis

The 10-K filing reveals a company at a crossroads between a high-conviction technological breakthrough and a looming liquidity crisis. While the exozyme platform offers a compelling scientific alternative to synthetic biology, the financial data indicates a race against time to achieve commercial viability before cash reserves are exhausted. The transition to a 'nutraceutical-first' strategy is a pragmatic attempt to shorten the time to revenue, but the lack of an established distribution network and the reliance on external CMOs leave the company exposed to operational risks. Ultimately, the investment thesis hinges on whether the 2026 commercialization milestones for NCT can be met with the remaining capital. If eXoZymes can successfully secure a strategic partnership or a high-value licensing deal, it may validate its platform and unlock significant value. However, without a near-term infusion of capital or a rapid pivot to revenue, the company risks becoming a cautionary tale of a scientifically sound platform that failed to navigate the 'valley of death' of early-stage biotech commercialization.